Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of specific identification tau antibody, and reagent kit containing thereof

A technology for specific identification and diagnostic kits, which can be used in testing pharmaceutical preparations, biological tests, anti-animal/human immunoglobulins, etc., and can solve problems such as omissions

Inactive Publication Date: 2013-04-10
INNOGENETICS NV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these diagnostic methods only allow detection of more severe stages of CNS damage, and early CNS damage that is present and ongoing may be missed by these methods

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of specific identification tau antibody, and reagent kit containing thereof
  • Application of specific identification tau antibody, and reagent kit containing thereof
  • Application of specific identification tau antibody, and reagent kit containing thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0095] Example 1: Elevated tau levels in children with leukemia

[0096] To evaluate the effect of chemotherapy on neuronal damage, an in-depth study was performed that included 65 leukemic children (2 to 16 years) treated according to standard procedures, without measurable central nervous system lesions. A total of 377 CSF samples were analyzed. Before each injection, a small amount of fluid was collected for routine laboratory analysis and the remainder was used in our study. The children were diagnosed and treated for leukemia at the Leuven University Hospital in Belgium. Tau protein in cerebrospinal fluid was assessed using INNOTEST hTAU antigen (Gent Innogenetics, Belgium).

[0097] Before starting treatment, perform a lumbar puncture in all children suspected of having leukemia to detect the possible presence of leukemic cells, an indication of central nervous system infiltration. The tau levels measured at this time, ie, before treatment, serve as control levels to ...

Embodiment 2

[0099] Example 2: Elevated levels of tau in leukemia patients before treatment

[0100] 1. Research object

[0101] Between August 1996 and June 1999, 510 CSF samples were collected from 82 children receiving cancer treatment at the Children's Hematology-Oncology Unit of the Catholic University in Leuven, Belgium. CSF samples were only taken during lumbar puncture (LP) scheduled for malignancy staging or treatment.

[0102] Three groups of patients with hematologic malignancies were studied. The largest cohort consisted of 48 non-B-ALL patients treated according to EORTC protocol 58881 (Table 1). Of these children, 20 had CD10(+) blasts (or common ALL), 2 of whom also had Down syndrome (DS), 1 had Brachmann-de Lange syndrome; 6 had common 2 patients had normal T-blasts, 2 patients had pro-B-blasts, 9 patients had pre-B-blasts, and 9 patients had T-blasts. Forty-two children had leukemia, and six patients had stage II (one), III (four), or IV (one) non-Hodgkin's lymphoma. ...

Embodiment 3

[0113] Example 3: Use of CSF-τ as a marker for early detection of possible CNS damage from stroke

[0114] 1. Research object

[0115] Seven patients participated in the study, 3 males and 4 females, aged 63-81 (mean SD, 70.7±7.2 years old), suffering from cerebral infarction, admitted to Sweden Neurology ward at Sahlgren University Hospital. All patients were enrolled in the study within 72 hours of stroke onset.

[0116] 2. Method

[0117] CSF samples were collected by lumbar puncture. Collect 12 ml and freeze each 0.5 ml at -80°C until analysis. CSF samples were collected on admission (day 0-1), day 2-3, day 7-8, day 21-22 (3 weeks), and day 90-110 (3 months). CSF-τ levels were determined by sandwich ELISA (INNOTEST ThTAU antigen, Gent Innogenetics Ltd., Belgium), measuring total tau (normal and hyperphosphorylated tau).

[0118] Brain computed tomography (CT) was used to check the extent of brain damage on the first day of admission. The modified Scandinavian Stro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a new method for the early diagnosis of CNS damage in an individual, said CNS damage being caused by space-occupying lesions of the CNS, by invasion or metastasis of the CNS, by organisms, by anoxia or ischemia, by chemical agents, by physical agents, or by a combination of these mechanisms. This new method comprises the step of determining and / or quantifying the level of tau in said individual and comparing it to the level of tau in control healthy individuals.

Description

[0001] This application is a divisional application of Chinese Patent Application No. 99812850.3 "Tau as Early CNS Damage Marker" filed on September 7, 1999. technical field [0002] The present invention relates to the field of CNS injuries. The present invention relates to a new method for early diagnosis of CNS damage through the detection and / or quantification of tau. Background technique [0003] Injuries to the central nervous system (CNS injuries) are caused by various causes, among them different disease processes, physical or chemical factors, hypoxia and ischemia. The disease process includes space-occupying lesions, brain invasion or metastasis by different malignancies, and / or infection with multiple pathogens. [0004] CNS tumors may be locally primary (primary tumors) or may have spread to the CNS (metastases). The primary tumor is composed of glial cells (astrocytoma, oligodendroglioma, glioblastoma), ependymal cells (ependymoma), or supporting tissue (menin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/574G01N33/68G01N33/577G01N33/53C07K16/18G01N33/15G01N33/50
CPCG01N33/6896G01N33/574
Inventor F·胡尔斯塔尔特E·范梅彻伦H·范德尔斯蒂彻勒A·范德沃德S·范古尔
Owner INNOGENETICS NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com